CXS Chemgenex Fpo

ChemGenex Pharmaceuticals Limited (ASX:CXS) will host an investor teleconference on Thursday 6th May at 11am Australian Eastern Standard Time (Wednesday 5th May at 6.00pm US Pacific time) to provide an update on the regulatory status of the company’s lead product, OMAPRO, in the US and Europe.

As part of an ongoing investor awareness program Greg Collier, Ph.D., Chief Executive Officer and Managing Director, ChemGenex will be presenting an update at the RBS Morgans Life Science conference in Sydney today, Tuesday 4th May 2010.

An updated version of the company’s overview presentation is available at http://www.chemgenex.com/investors/presentations.

Investor teleconference details

The teleconference will be held on Thursday 6th May 11am AEST / Wednesday 5th May 6pm PDT.

International toll free access numbers:

    Australia 1800 152 721 Australia (metered call) +61 2 8212 8333 USA/ Canada 1866 307 0659 France 0805100294 Germany 08000003882 Hong Kong 800933733 Indonesia 0018030113830 New Zealand 0800084460 Singapore 8006162259 Switzerland 0800000601 United Kingdom 08082389067  

Participant Pin No:

480377#

Dial in details for any other locations or further information is available from Kyahn Williamson - kwilliamson@bcg.com.au / +61 40 101 8828.

About ChemGenex Pharmaceuticals Limited

ChemGenex is an oncology focused biopharmaceutical company developing small molecules with new mechanisms of action to treat malignancies with significant unmet medical needs. A New Drug Application has been accepted by the U.S. Food and Drug Administration and a Marketing Authorisation Application has been validated by the European Medicines Agency for CML patients who have failed imatinib therapy and have the Bcr-Abl T315I mutation. ChemGenex has established a corporate alliance with Hospira to develop and commercialize omacetaxine in Europe, the Middle East and parts of Africa, and is seeking to establish commercial partnerships in the rest of the world. ChemGenex plans to commercialize omacetaxine itself in North America. ChemGenex trades on the Australian Stock Exchange under the symbol "CXS" For additional information on ChemGenex Pharmaceuticals, please visit the company’s website at http://www.chemgenex.com.

OMAPRO™ is a trademark of ChemGenex Pharmaceuticals Limited.

Safe Harbor Statement

Certain statements made herein (including for this purpose sites to which a hyperlink has been provided) that use the words “estimate”, “project”, “intend”, “expect”, “believe” and similar expressions are intended to identify forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties which could cause the actual results, performance or achievements of the company to be materially different from those which may be expressed or implied by such statements, including, among others, risks or uncertainties associated with the development of the company’s technology, the ability to successfully market products in the clinical pipeline, the ability to advance promising therapeutics through clinical trials, the ability to establish our fully integrated technologies, the ability to enter into additional collaborations and strategic alliances and expand current collaborations and obtain milestone payments, the suitability of internally discovered genes for drug development, the ability of the company to meet its financial requirements, the ability of the company to protect its proprietary technology, potential limitations on the company’s technology, the market for the company’s products, government regulation in Australia and the United States, changes in tax and other laws, changes in competition and the loss of key personnel. These statements are based on our management’s current expectations and are subject to a number of uncertainties that could change the results described in the forward-looking statements. Investors should be aware that there are no assurances that results will not differ from those projected.